Regeneron PharmaceuticalsNASDAQ: REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will be participating in the Jefferies London Healthcare Conference on November 19, 2024, at 6:00 AM ET. The company will have representatives including Ryan Crowe, Senior Vice President of Investor Relations and Strategic Analysis, and Marion McCourt, Executive Vice President of Commercial. Akash Tewari from Jefferies will also be part of the conference call.

Biotech stocks, such as Regeneron, have dropped significantly because of regulatory and political issues, which might create a good chance to buy as sellers seem to be losing interest. Regeneron's 40% decline is influenced by worries about Eylea's market position, lawsuits from the DOJ, and overall uncertainty in the sector. Even with this decline, Regeneron is still a very profitable company with a strong product pipeline, currently valued very low and showing promise for long-term growth.

The FDA has agreed to review the resubmission of Dupixent's supplemental biologics license application for treating chronic spontaneous urticaria (CSU) in adults and children aged 12 and older. This new submission includes important data showing that Dupixent significantly reduces itching and hives. If approved, Dupixent would be the first targeted treatment for CSU in ten years, with a decision expected by April 18, 2025.

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will stream a webcast featuring its management team as detailed below:

Dupixent has been approved in the EU as the first and only treatment for young children with eosinophilic esophagitis. This approval is based on phase 3 studies showing that significantly more children aged one to 11 on Dupixent achieved disease remission after 16 weeks compared to those on a placebo, with results lasting up to a year. This makes Dupixent the first medicine in the EU for these young patients, who face challenges with eating during a crucial growth period.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a prominent national law firm focused on shareholder rights, has started an investigation into Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) regarding possible breaches of federal securities laws. If you experienced a loss on your Regeneron investments or are interested in exploring claims to recover your losses, please reach out for more information.

Regeneron's stock dropped by 9.2% following the Q3 2024 report, which made the company's valuation look more appealing. This report was the 15th out of 16 in the past four years that exceeded expectations. Investors were concerned about the slowing sales growth of EYLEA and the uncertain revenue forecasts for 2024.

Regeneron's stock is dropping sharply due to recent legal issues with Eylea and Amgen introducing a lower-dose biosimilar version of the drug. However, investors might be exaggerating the negative effects of this situation. Meanwhile, Dupixent continues to grow rapidly with increasing profit margins from collaborations, and Libtayo is also showing strong revenue growth.

Regeneron has announced third-quarter results that exceeded expectations, surpassing both earnings and revenue forecasts. This success is mainly due to strong sales of Eylea HD, Dupixent, and Libtayo.